Ferrari-Toninelli Giulia, Maccarinelli Giuseppina, Uberti Daniela, Buerger Erich, Memo Maurizio
Department of Biomedical Sciences and Biotechnologies and National Institute of Neuroscience, University of Brescia, Brescia, Italy.
BMC Pharmacol. 2010 Feb 5;10:2. doi: 10.1186/1471-2210-10-2.
Pramipexole exists as two isomers. The S(-) enantiomer is a potent D3/D2 receptor agonist and is extensively used in the management of PD. In contrast, the R(+) enantiomer is virtually devoid of any of the DA agonist effects. Very limited studies are available to characterize the pharmacological spectrum of the R(+) enantiomer of pramipexole.
Using differentiated SH-SY5Y neuroblastoma cells as an experimental model, here we show that S(-) and R(+) pramipexole are endowed with equipotent efficacy in preventing cell death induced by H2O2 and inhibiting mitochondrial reactive oxygen species generation. Both pramipexole enantiomers prevented mitochondrial ROS generation with a potency about ten times higher then that elicited for neuroprotection.
These results support the concept of both S(-) and R(+) pramipexole enantiomers as mitochondria-targeted antioxidants and suggest that the antioxidant, neuroprotective activity of these drugs is independent of both the chiral 6-propylamino group in the pramipexole molecule and the DA receptor stimulation.
普拉克索存在两种异构体。S(-)对映体是一种强效的D3/D2受体激动剂,广泛用于帕金森病的治疗。相比之下,R(+)对映体几乎没有任何多巴胺激动剂效应。关于普拉克索R(+)对映体的药理学谱的研究非常有限。
以分化的SH-SY5Y神经母细胞瘤细胞作为实验模型,我们在此表明,S(-)和R(+)普拉克索在预防过氧化氢诱导的细胞死亡和抑制线粒体活性氧生成方面具有同等效力。两种普拉克索对映体均能预防线粒体活性氧的生成,其效力比神经保护作用高约十倍。
这些结果支持S(-)和R(+)普拉克索对映体均为线粒体靶向抗氧化剂的概念,并表明这些药物的抗氧化、神经保护活性与普拉克索分子中的手性6-丙氨基基团和多巴胺受体刺激均无关。